Biocon Limited has announced its participation in key investor conferences scheduled for mid-April 2026, as part of its ongoing engagement with the investment community. The company has formally notified stock exchanges about these meetings in compliance with SEBI Listing Regulations.

Scheduled Investor Conferences

The biotechnology company's management will participate in two significant investor events during April 2026:

These events will provide opportunities for direct engagement between Biocon's management team and institutional investors through both individual and group meetings.

Regulatory Compliance and Information Disclosure

Biocon has emphasized its commitment to regulatory compliance during these investor interactions. The company has specifically stated that no Unpublished Price Sensitive Information (UPSI) will be disclosed during the analyst and investor meetings. This adherence to SEBI guidelines ensures transparency while maintaining market integrity.

The notification was filed pursuant to Regulation 30(6) of the SEBI Listing Regulations, demonstrating the company's commitment to keeping stakeholders informed about management's engagement activities.

Event Flexibility and Accessibility

The company has noted that the mentioned schedule may be subject to change due to exigencies on the part of investors or the company. This flexibility allows for adjustments based on participant availability and other operational considerations.

Additional information regarding these investor meetings will be made available on the company's official website at www.biocon.com , ensuring broader accessibility for stakeholders who wish to stay updated on the company's investor relations activities.

Biocon Limited has submitted its quarterly compliance certificate under Regulation 74(5) of the Securities and Exchange Board of India (Depositories and Participants) Regulations, 2018 for the quarter ended March 31, 2026. The certificate was filed with both BSE Limited and National Stock Exchange of India Limited on April 07, 2026.

Regulatory Compliance Certificate

The certificate confirms that Biocon has furnished details of securities dematerialized and rematerialized during the quarter ended March 31, 2026 to all stock exchanges where the company's shares are listed. This filing is a mandatory requirement under SEBI regulations to ensure transparency in share transfer processes.

Registrar Confirmation

KFin Technologies Limited, serving as Biocon's Registrar and Share Transfer Agent, provided confirmation dated April 04, 2026 regarding compliance with regulatory requirements. The registrar confirmed that during the period from January 1, 2026 to March 31, 2026, all dematerialization processes were handled in accordance with SEBI regulations.

Key Compliance Activities

KFin Technologies confirmed completion of the following regulatory requirements:

• Confirmed demat requests within 15 days of receipt from depository participants
• Verified that securities in certificates were listed on appropriate stock exchanges
• Properly mutilated and cancelled security certificates after verification
• Updated member registers with depository names as registered owners for approved demat requests

Corporate Filing Details

The certificate was signed by Rajesh Umakant Shanoy, Company Secretary and Compliance Officer of Biocon Limited, with membership number ACS 16328. The filing was made to both major Indian stock exchanges where Biocon shares are traded.

This quarterly filing demonstrates Biocon's ongoing commitment to regulatory compliance and transparency in its share transfer and dematerialization processes as required under SEBI guidelines.